John M. Burke, MD from Rocky Mountain Cancer Centers discusses multiple myeloma study and added daratumumab towards CD38 at the 2017 American Society of Hematology.
Multiple Myeloma Study – Added daratumumab towards CD38
Advertisement
[the_ad id="32629"]